WO2002054066A3 - Non-apoptotic forms of cell death and methods of modulation - Google Patents

Non-apoptotic forms of cell death and methods of modulation Download PDF

Info

Publication number
WO2002054066A3
WO2002054066A3 PCT/US2001/048261 US0148261W WO02054066A3 WO 2002054066 A3 WO2002054066 A3 WO 2002054066A3 US 0148261 W US0148261 W US 0148261W WO 02054066 A3 WO02054066 A3 WO 02054066A3
Authority
WO
WIPO (PCT)
Prior art keywords
paraptosis
methods
cell death
modulation
caspase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/048261
Other languages
French (fr)
Other versions
WO2002054066A2 (en
Inventor
Sabina Sperandio
Belle Ian De
Dale E Bredesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Priority to AU2002248180A priority Critical patent/AU2002248180A1/en
Priority to DE60140074T priority patent/DE60140074D1/en
Priority to EP01997059A priority patent/EP1342085B1/en
Priority to AT01997059T priority patent/ATE444488T1/en
Publication of WO2002054066A2 publication Critical patent/WO2002054066A2/en
Publication of WO2002054066A3 publication Critical patent/WO2002054066A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

The invention is directed to methods for identifying molecules that modulate paraptosis, a newly identified nonapoptotic form of programmed cell death. The invention also provides a method of inhibiting paraptosis by preventing association of caspase-9 and an endogenous paraptosis-mediating molecule. In one embodiment, the invention provides a method of inhibiting paraptosis by preventing association of caspase-9 and the Insulin-Like Growth Factor I Receptor (IGFIR). The invention further is directed to therapeutic methods for treatment of pathologies associated with aberrant levels of paraptosis such as neural cell death disorders and neoplastic disorders. Also provided by the present invention are methods of identifying endogenous paraptosis-mediating molecules.
PCT/US2001/048261 2000-12-14 2001-12-13 Non-apoptotic forms of cell death and methods of modulation Ceased WO2002054066A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002248180A AU2002248180A1 (en) 2000-12-14 2001-12-13 Non-apoptotic forms of cell death and methods of modulation
DE60140074T DE60140074D1 (en) 2000-12-14 2001-12-13 Non-apoptotic forms of cell death and method of modulation
EP01997059A EP1342085B1 (en) 2000-12-14 2001-12-13 Non-apoptotic forms of cell death and methods of modulation
AT01997059T ATE444488T1 (en) 2000-12-14 2001-12-13 NON-APOPTOTIC FORMS OF CELL DEATH AND METHOD FOR MODULATION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25602300P 2000-12-14 2000-12-14
US60/256,023 2000-12-14
US25669400P 2000-12-19 2000-12-19
US60/256,694 2000-12-19

Publications (2)

Publication Number Publication Date
WO2002054066A2 WO2002054066A2 (en) 2002-07-11
WO2002054066A3 true WO2002054066A3 (en) 2002-10-31

Family

ID=26945108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048261 Ceased WO2002054066A2 (en) 2000-12-14 2001-12-13 Non-apoptotic forms of cell death and methods of modulation

Country Status (6)

Country Link
US (1) US20090263852A1 (en)
EP (1) EP1342085B1 (en)
AT (1) ATE444488T1 (en)
AU (1) AU2002248180A1 (en)
DE (1) DE60140074D1 (en)
WO (1) WO2002054066A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
FI20030130A0 (en) 2003-01-29 2003-01-29 Licentia Oy screening method
JP2007510434A (en) 2003-11-12 2007-04-26 シェーリング　コーポレイション A plasmid system for multigene expression.
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
WO2007139961A1 (en) * 2006-05-25 2007-12-06 The University Of Chicago Methods of reducing cell death following hypoxia / reoxygenation
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
EP3791870A1 (en) * 2013-12-02 2021-03-17 The Trustees of Columbia University in the City of New York Modulating ferroptosis and treating excitotoxic disorders
CA2940460A1 (en) * 2014-03-07 2015-09-11 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
ES2904301T3 (en) 2014-11-03 2022-04-04 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Anti-Bob1 T cell receptors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63218681A (en) * 1987-03-09 1988-09-12 Mitsubishi Kasei Corp Oligomycin E
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5752515A (en) * 1996-08-21 1998-05-19 Brigham & Women's Hospital Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
US6063758A (en) * 1997-07-09 2000-05-16 Advanced Targeting Systems, Inc. Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US7119114B1 (en) * 1999-08-19 2006-10-10 Signal Pharmaceuticals, Llc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
ATE329899T1 (en) * 2000-03-27 2006-07-15 Applied Research Systems PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS
CN1604776A (en) * 2001-10-16 2005-04-06 记忆药物公司 4-4-alkoxy-3-hydroxyphenyl-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US6994981B2 (en) * 2002-02-19 2006-02-07 The Buck Institute Modulators of paraptosis and related methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63218681A (en) * 1987-03-09 1988-09-12 Mitsubishi Kasei Corp Oligomycin E
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MAJNO G ET AL: "APOPTOSIS ONCOSIS AND NECROSIS AN OVERVIEW OF CELL DEATH", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 146, no. 1, January 1995 (1995-01-01), pages 3 - 15, XP000884170, ISSN: 0002-9440 *
OPPENHEIM RONALD W ET AL: "Programmed cell death of developing mammalian neurons after genetic deletion of caspases.", JOURNAL OF NEUROSCIENCE, vol. 21, no. 13, 1 July 2001 (2001-07-01), pages 4752 - 4760, XP001084981, ISSN: 0270-6474 *
RESNICOFF M ET AL: "The insulin -like growth factor I receptor protects tumor cells from apoptosis in vivo", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 11, 1995, pages 2463 - 2469, XP002124515, ISSN: 0008-5472 *
SPERANDIO S ET AL: "A proteomic approach to the characterization of non-apoptotic programmed cell death.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001, pages 869, XP001083701, ISSN: 0190-5295 *
SPERANDIO SABINA ET AL: "An alternative, nonapoptotic form of programmed cell death.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 26, 19 December 2000 (2000-12-19), December 19, 2000, pages 14376 - 14381, XP002204088, ISSN: 0027-8424 *
TURMAINE M ET AL: "NONAPOPTOTIC NEURODEGENERATION IN A TRANGENIC MOUSE MODEL OF HUNTINGTON'S DISEASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 14, 5 July 2000 (2000-07-05), pages 8093 - 8097, XP000990139, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2002248180A1 (en) 2002-07-16
US20090263852A1 (en) 2009-10-22
EP1342085A2 (en) 2003-09-10
DE60140074D1 (en) 2009-11-12
WO2002054066A2 (en) 2002-07-11
ATE444488T1 (en) 2009-10-15
EP1342085B1 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
MX9606401A (en) Indolinone compounds for the treatment of disease.
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2002054066A3 (en) Non-apoptotic forms of cell death and methods of modulation
BR0114630A (en) Growth Hormone Secretagogues
EP1137658A4 (en) TECHNIQUES FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES INDUCED BY TUMOR NECROSIS FACTOR- $ g (a)
AU7585598A (en) Raf kinase inhibitors
DE69815090D1 (en) USE OF CHOLINESTERASE INHIBITORS FOR TREATING CONCENTRATIONAL DISORDER
WO2003079020A3 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2025057134A3 (en) Glp-1r agonist and therapeutic method thereof
WO2000013706A8 (en) Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
NO20010389L (en) Modulation of multiple line kinase proteins
ATE222119T1 (en) USE OF ERYTHROPOIETIN TO TREAT MULTIPLE MYELOMA
ATE306264T1 (en) USE OF ACETYLCHOLINESTERASE INHIBITORS TO MODULATE THE HYPOTHALAMUS-PITOPHYSIS-GONAD AXIS
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
NO20052267L (en) Compounds, Preparations and Methods
WO2002066045A3 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
ATE288498T1 (en) METHODS FOR INHIBITING HELICOBACTER PYLORI
WO2002017858A3 (en) Role of fosb in bone formation
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
DE69905489D1 (en) PROTEIN C FOR THE TREATMENT OF SICKLE LEMENIA AND THALASSEMIA
WO2003037257A3 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
WO2002062297A3 (en) Methods and compositions for modulating gluconeogenesis using pgc-1
GB0016362D0 (en) Tetraspanin modulation
IL142255A0 (en) Method of treating heparin-induced thrombocytopenia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001997059

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001997059

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP